Genvec INC (WKN: 580662)
49 Postings ausgeblendet.
12.04.10 14:44
#51
_bbb_
News !
Encouraging Data From Malaria Study Presented
Date : 04/12/2010 @ 7:44AM
Source : PR Newswire
Stock : Genvec (MM) (GNVC)
Quote : 0.7101 0.0 (0.00%) @ 8:36AM
Encouraging Data From Malaria Study Presented
Encouraging Data From Malaria Study Presented
PR Newswire
GAITHERSBURG, Md., April 12
GAITHERSBURG, Md., April 12 /PRNewswire-FirstCall/ --
GenVec, Inc. (Nasdaq: GNVC) announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium -- Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain, Colorado.
Safety, tolerability, immunogenicity, and efficacy data from the Phase 1/2a malaria trial using GenVec technology were presented. Data indicate malaria vaccines given to malaria-naive adults were found to be safe and well-tolerated with minimal local or systemic reactions and no serious vaccine-related adverse reactions. Sterile protection, a complete absence of parasites in the blood, was seen in 4 out of 15 volunteers that had been inoculated with the vaccine and subsequently challenged with the malaria parasite.
This clinical trial is being conducted under sponsorship from the United States Army Medical Materiel Development Activity (USAMMDA) and with financial support from the U.S. Agency for International Development, the Congressionally Directed Peer Review Medical Program, and the Military Infectious Diseases Research Program.
"The results of this study are encouraging and we are looking forward to gaining more insight regarding the potential for this vaccine," stated Dr. Douglas Brough, GenVec's Vice President of Research.
About Malaria
Malaria is one of the world's leading lethal infectious diseases. Malaria is a life-threatening disease transmitted to humans through the bite of an infected mosquito. Malaria parasites initially invade liver cells and, after multiplying, release tens of thousands of new parasites, which invade red blood cells, multiply again, and then destroy these cells. High fever, headache, and vomiting appear approximately nine to fourteen days after the infectious bite. If untreated, the infection can progress rapidly and become life threatening -- destroying red blood cells, causing severe anemia, and blocking capillaries that carry blood to the brain, resulting in coma and/or death. Malaria causes approximately 243 million acute illnesses and 863,000 deaths annually, mostly among children under the age of five. Malaria is a major health risk for travelers and the military.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses its proprietary adenovector technology to develop TNFerade for the treatment of certain cancers and vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.
Investor Contact:
Media Contact:
GenVec, Inc.
Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro
Andrew Mielach
(301) 944-1877
(212) 827-0020
ddipirro@genvec.com
amielach@tiberendstrategicadvisors.com
SOURCE GenVec, Inc.
Date : 04/12/2010 @ 7:44AM
Source : PR Newswire
Stock : Genvec (MM) (GNVC)
Quote : 0.7101 0.0 (0.00%) @ 8:36AM
Encouraging Data From Malaria Study Presented
Encouraging Data From Malaria Study Presented
PR Newswire
GAITHERSBURG, Md., April 12
GAITHERSBURG, Md., April 12 /PRNewswire-FirstCall/ --
GenVec, Inc. (Nasdaq: GNVC) announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium -- Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain, Colorado.
Safety, tolerability, immunogenicity, and efficacy data from the Phase 1/2a malaria trial using GenVec technology were presented. Data indicate malaria vaccines given to malaria-naive adults were found to be safe and well-tolerated with minimal local or systemic reactions and no serious vaccine-related adverse reactions. Sterile protection, a complete absence of parasites in the blood, was seen in 4 out of 15 volunteers that had been inoculated with the vaccine and subsequently challenged with the malaria parasite.
This clinical trial is being conducted under sponsorship from the United States Army Medical Materiel Development Activity (USAMMDA) and with financial support from the U.S. Agency for International Development, the Congressionally Directed Peer Review Medical Program, and the Military Infectious Diseases Research Program.
"The results of this study are encouraging and we are looking forward to gaining more insight regarding the potential for this vaccine," stated Dr. Douglas Brough, GenVec's Vice President of Research.
About Malaria
Malaria is one of the world's leading lethal infectious diseases. Malaria is a life-threatening disease transmitted to humans through the bite of an infected mosquito. Malaria parasites initially invade liver cells and, after multiplying, release tens of thousands of new parasites, which invade red blood cells, multiply again, and then destroy these cells. High fever, headache, and vomiting appear approximately nine to fourteen days after the infectious bite. If untreated, the infection can progress rapidly and become life threatening -- destroying red blood cells, causing severe anemia, and blocking capillaries that carry blood to the brain, resulting in coma and/or death. Malaria causes approximately 243 million acute illnesses and 863,000 deaths annually, mostly among children under the age of five. Malaria is a major health risk for travelers and the military.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses its proprietary adenovector technology to develop TNFerade for the treatment of certain cancers and vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.
Investor Contact:
Media Contact:
GenVec, Inc.
Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro
Andrew Mielach
(301) 944-1877
(212) 827-0020
ddipirro@genvec.com
amielach@tiberendstrategicadvisors.com
SOURCE GenVec, Inc.
13.04.10 09:01
#57
_bbb_
...
Hearing Loss Could Be A Win For GenVec
Madalina Iacob, 03.30.10, 03:15 PM EDT
Biopharma's shares plummet after it discontinues cancer drug trial but analyst still sees upside.
GenVec, Inc.04/12/2010 4:00PM ET$0.76$0.057.04%
At A GlanceChartNewsPeople
Full GNVC Chart at
Novartis AG04/12/2010 4:00PM ET$53.48$0.370.70%
At A GlanceChartNewsPeople
Full NVS Chart at
BATS Real-Time Market Data by XigniteA failed trial on a pancreatic cancer drug sucked the life out of GenVec shares Tuesday, but the steep decline may be setting up an attractive entry point for investors if a separate collaboration with Novartis works out.
GenVec ( GNVC - news - people ) shares plunged as low as 71 cents early in the session and were down 72%, or $2.02, to 78 cents with an hour to the close after the company announced it is shelving a Phase 3 clinical trial for TNFerade in patients with pancreatic cancer.
Article Controls
email
print
reprint
newsletter
comments
share
del.icio.us
Digg It!
yahoo
Facebook
Twitter
Reddit
rss
Yahoo! Buzz"We are disappointed with data, particularly given the lack of adequate treatments for pancreatic cancer," said Paul Fischer, Ph.D., the CEO of GenVec. "As our shareholders know in addition to TNFerade our research consists of a number of funded vaccine programs. We will continue to focus on those programs and supporting our collaboration with Novartis ( NVS - news - people ) to develop treatments for hearing loss."
Discontinuing the TNFerade trial will slow down the rate at which GenVec burns through the $38 million in cash on its balance sheet, and Nathan Cali, an analyst with Noble Financial Capital Markets, thinks the $213.6 million partnership with Novartis could pay off and is advising clients to buy GenVec shares at their newly reduced price.
The deal with Novartis, sealed in early 2010, gives the pharmaceutical heavyweight global rights to GenVec's preclinical hearing loss and balance disorders programs.
Cali acknowledges that there is a substantial risk involved in the program, but even with only a 15% chance of clinical success, the opportunity in the $4.5 billion hearing loss market--where the industry standard is hearing aids and not pharmaceuticals--GenVec shares could get a major boost if the treatment can show encouraging results in early-stage trials.
Rate This Story
Your Rating
Overall Rating
Reader Comments
Post a Comment
http://www.forbes.com/2010/03/30/...uities-cancer.html?partner=alerts
Madalina Iacob, 03.30.10, 03:15 PM EDT
Biopharma's shares plummet after it discontinues cancer drug trial but analyst still sees upside.
GenVec, Inc.04/12/2010 4:00PM ET$0.76$0.057.04%
At A GlanceChartNewsPeople
Full GNVC Chart at
Novartis AG04/12/2010 4:00PM ET$53.48$0.370.70%
At A GlanceChartNewsPeople
Full NVS Chart at
BATS Real-Time Market Data by XigniteA failed trial on a pancreatic cancer drug sucked the life out of GenVec shares Tuesday, but the steep decline may be setting up an attractive entry point for investors if a separate collaboration with Novartis works out.
GenVec ( GNVC - news - people ) shares plunged as low as 71 cents early in the session and were down 72%, or $2.02, to 78 cents with an hour to the close after the company announced it is shelving a Phase 3 clinical trial for TNFerade in patients with pancreatic cancer.
Article Controls
reprint
newsletter
comments
share
del.icio.us
Digg It!
yahoo
rss
Yahoo! Buzz"We are disappointed with data, particularly given the lack of adequate treatments for pancreatic cancer," said Paul Fischer, Ph.D., the CEO of GenVec. "As our shareholders know in addition to TNFerade our research consists of a number of funded vaccine programs. We will continue to focus on those programs and supporting our collaboration with Novartis ( NVS - news - people ) to develop treatments for hearing loss."
Discontinuing the TNFerade trial will slow down the rate at which GenVec burns through the $38 million in cash on its balance sheet, and Nathan Cali, an analyst with Noble Financial Capital Markets, thinks the $213.6 million partnership with Novartis could pay off and is advising clients to buy GenVec shares at their newly reduced price.
The deal with Novartis, sealed in early 2010, gives the pharmaceutical heavyweight global rights to GenVec's preclinical hearing loss and balance disorders programs.
Cali acknowledges that there is a substantial risk involved in the program, but even with only a 15% chance of clinical success, the opportunity in the $4.5 billion hearing loss market--where the industry standard is hearing aids and not pharmaceuticals--GenVec shares could get a major boost if the treatment can show encouraging results in early-stage trials.
Rate This Story
Your Rating
Overall Rating
Reader Comments
Post a Comment
http://www.forbes.com/2010/03/30/...uities-cancer.html?partner=alerts
13.04.10 11:44
#61
_bbb_
...
ich rechne mit einer gewaltigen Gegenreaktion...
Shorties müssten auch noch covern.
GenVec Inc. $ 0.76
GNVC 0.05
Short Interest (Shares Short) 15,718,900
Days To Cover (Short Interest Ratio) 1.4
Short Percent of Float 16.81 %
Short Interest - Prior 13,256,800
Short % Increase / Decrease 18.57 %
Short Squeeze Ranking™ 6
% From 52-Wk High ($ 3.35 ) -340.79 %
% From 52-Wk Low ($ 0.44 ) 42.11 %
% From 200-Day MA ($ 1.27 ) -67.11 %
% From 50-Day MA ($ 2.17 ) -185.53 %
Price % Change (52-Week) 26.80 %
Shares Float 93,481,566
Total Shares Outstanding 124,871,515
% Owned by Insiders 4.60 %
% Owned by Institutions 9.50 %
Market Cap. $ 94,902,351
Trading Volume - Today 9,032,436
Trading Volume - Average 11,510,400
Trading Volume - Today vs. Average 78.47 %
Earnings Per Share -0.19
PE Ratio
Record Date 2010-AprA
Sector Healthcare
Industry Biotechnology
Exchange NAS
Shorties müssten auch noch covern.
GenVec Inc. $ 0.76
GNVC 0.05
Short Interest (Shares Short) 15,718,900
Days To Cover (Short Interest Ratio) 1.4
Short Percent of Float 16.81 %
Short Interest - Prior 13,256,800
Short % Increase / Decrease 18.57 %
Short Squeeze Ranking™ 6
% From 52-Wk High ($ 3.35 ) -340.79 %
% From 52-Wk Low ($ 0.44 ) 42.11 %
% From 200-Day MA ($ 1.27 ) -67.11 %
% From 50-Day MA ($ 2.17 ) -185.53 %
Price % Change (52-Week) 26.80 %
Shares Float 93,481,566
Total Shares Outstanding 124,871,515
% Owned by Insiders 4.60 %
% Owned by Institutions 9.50 %
Market Cap. $ 94,902,351
Trading Volume - Today 9,032,436
Trading Volume - Average 11,510,400
Trading Volume - Today vs. Average 78.47 %
Earnings Per Share -0.19
PE Ratio
Record Date 2010-AprA
Sector Healthcare
Industry Biotechnology
Exchange NAS
15.04.10 09:27
#63
ridgeback
GenVec presents...
http://www.thepharmaletter.com/file/...rom-malaria-vaccine-study.html
29.04.10 23:15
#64
_bbb_
bin erstmal draussen...
http://ih.advfn.com/p.php?pid=nmona&article=42598923
LESEN !
LESEN !
08.05.10 18:54
#65
ridgeback
GenVec Reports First Quarter 2010
http://www.prnewswire.com/news-releases/...cial-results-92997484.html
hätte schlimmer sein können. bleibe weiterhin inverstiert, da dieses unternehmen noch viel potential und einige burner in der pipeline hat.
hätte schlimmer sein können. bleibe weiterhin inverstiert, da dieses unternehmen noch viel potential und einige burner in der pipeline hat.
15.12.10 11:11
#68
Nordi63
Das war die letzte Meldung.
http://www.ariva.de/news/...ckziehen-Global-Biotech-Investing-3368606
Aber ich sehe langsam die Zeit für einen Neueinstieg gekommen.
Es waren ja noch mehr Produkte in der Pipeline.
MfG Nordi63
Aber ich sehe langsam die Zeit für einen Neueinstieg gekommen.
Es waren ja noch mehr Produkte in der Pipeline.
MfG Nordi63
0,3292 (+123.76%)